Phreesia, Inc. (PHR)

In August 2025, analysts maintained strong buy ratings, and the stock showed a modest increase. In September 2025, the company reported second-quarter 2026 earnings, with EPS exceeding analyst expectations. In November 2025, the stock experienced a decrease of over 10%. In December 2025, the stock price initially increased by over 10% but later decreased by over 10%; Phreesia shifted to GAAP profitability in Q3 2026. In January 2026, there were numerous insider selling transactions, and the share price declined significantly. By February 2026, the stock price was $12.59.

Specific information regarding demand seasonality is not directly provided; however, the company's Q3 2026 earnings report indicated consistent demand in its core intake and patient engagement products.

Phreesia, Inc. is a technology company in the Healthcare sector, providing an integrated SaaS-based software and payment platform. Its solutions include appointment scheduling, registration, revenue cycle management, network solutions, and various platform modalities like mobile apps, tablets, web dashboards, and on-site kiosks. Additional solutions include call-triaging, electronic forms, and a doctor finder.

Phreesia, Inc. primarily operates in the United States and Canada.

Phreesia has a generally positive brand reputation within the healthcare sector, recognized for its innovative approach and patient-centered solutions. The company has garnered attention from analysts, with strong buy ratings. The CEO was named one of The Software Report's Top 50 SaaS CEOs in 2025.

Phreesia, Inc.'s ownership is largely dominated by institutional investors, who collectively held a significant percentage of the company's shares. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Fmr Llc. Individual insiders, such as founders and executives, also hold a stake in the company.